Legend Biotech Announces Participation in Upcoming Investor Conference

May 11, 2023

SOMERSET, N.J.--(BUSINESS WIRE)--May 11, 2023-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. Ying Huang, PhD, CEO of Legend Biotech, will participate in a fireside chat on Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time).

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

Crystal Chen, Manager, Investor Relations, Legend Biotech

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
(908) 331-5025

Source: Legend Biotech Corporation


You are about to leave Investors.LegendBiotech.com